Zhai G, Pelletier JP, Liu M, et al. - One hundred fifty-eight OA persons who completed the study according to the protocol of a former 24-month clinical trial cohort contrasting the impact of licofelone vs naproxen in symptomatic knee OA people were involved in order to investigate whether serum lysophosphatidylcholines (lysoPCs) to phosphatidylcholines (PCs) ratio could prognosticate clinical response to licofelone and naproxen treatments in symptomatic knee OA people. Data exhibited that 61.4% of the people symptomatically responded to licofelone and naproxen and 38.6% were considered as therapeutic failures (non-responders). No variation in responders between licofelone and naproxen was noted. Responders had a significantly higher lysoPCs to PCs ratio compared with non-responders. Therefore, for the response to licofelone and naproxen, serum lysoPCs to PCs ratio is a marker and may it help in the personalized treatment to knee OA.